On July 29, 2026, a clinical trial update was recorded for a study involving insulin aspart. The trial, registered as NCT05946785 and titled "Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes," is currently listed with a status of recruiting.
The study is designated Early Phase 1. No results or outcome data have been reported as part of this update. The listing reflects only the trial's current recruitment status and phase designation as of the stated date.
Insulin aspart is an approved compound, and its inclusion in this study relates to its established regulatory status. This update does not describe findings, efficacy, or safety conclusions. It reflects only the administrative status of the trial as recorded in the registry entry.
Readers seeking further detail can consult the trial registration directly for eligibility criteria, study design, and sponsor information. For background on insulin aspart itself, see the compound overview for additional context.